MannKind Corporation (MNKD) Stock Price & Analysis
MannKind Corporation (MNKD) closed at USD 3.19 on Thursday, October 15, 2026, up 5.63% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.02; the Oct 15, 2026 session ranged USD 3–3.2 on volume of 3,756,529 shares. Market capitalization is $1.03B, with a 52-week range of USD 2.23–6.51 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MNKD.md
Key facts (MNKD)
- Last four reported quarters (through Jun 30, 2026): revenue $394M, net income -$43.6M (-11.1% margin), free cash flow -$18.1M (SEC filings).
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $791K; 0 not under a Rule 10b5-1 plan ($0K).
- Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 7.84 (range 4.75–13).
- Total return with dividends: 1Y -40.4% vs S&P 500 +18.1%; 5Y -37.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.01, revenue estimate $110M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MNKD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $75.4M | $99.8M | $199M | $286M | $349M | $394M |
| Gross profit | $58.6M | $83.8M | $178M | $268M | $322M | — |
| Operating income | -$47.0M | -$64.1M | $8.7M | $72.6M | $38.8M | $9.2M |
| Net income | -$80.9M | -$87.4M | -$11.9M | $27.6M | $5.9M | -$43.6M |
| EPS (diluted) | -$0.32 | -$0.34 | -$0.04 | $0.10 | $0.02 | — |
| Free cash flow | -$73.2M | -$88.3M | -$8.3M | $32.8M | $13.7M | -$18.1M |
| Gross margin | 77.7% | 84.0% | 89.5% | 93.9% | 92.3% | — |
| Operating margin | -62.3% | -64.3% | 4.4% | 25.4% | 11.1% | 2.3% |
| Net margin | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% | -11.1% |
| Revenue growth | +15.8% | +32.2% | +99.4% | +43.5% | +22.2% | — |
| Cash + short-term investments | $204M | $171M | $295M | $197M | $171M | — |
| Total debt | $281M | $273M | $269M | $36.1M | $355M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MNKD)
P/S 2.6x · EV/EBITDA 48.1x · EV/Sales 3.1x · FCF yield -1.77% · Earnings yield -4.25% · Net debt $208M · EV $1.23B
P/E at fiscal year-ends: Dec 2025 303.8x, Dec 2024 66.2x.
Insider sales (SEC Form 4, open-market, last ~7 months) (MNKD)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan |
|---|---|---|---|---|---|---|
| 2026-09-25 | Binder Steven B. | Director | 39,051 | $128K | 5.2% | Yes |
| 2026-09-10 | Binder Steven B. | Director | 33,558 | $128K | 4.3% | Yes |
| 2026-08-07 | Binder Steven B. | Director | 39,051 | $159K | 4.7% | Yes |
| 2026-07-17 | Thomson David | EVP Genl Counsel & Secretary | 24,109 | $98K | 2.9% | Yes |
| 2026-07-17 | Binder Steven B. | Director | 52,485 | $213K | 6% | Yes |
| 2026-05-12 | Binder Steven B. | Director | 16,940 | $56K | 2.1% | Yes |
| 2026-05-12 | Thomson David | EVP Genl Counsel & Secretary | 3,033 | $10K | 0.4% | Yes |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Analysts (MNKD)
Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 7.84 (low 4.75, high 13).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Truist Securities | Target lowered | Buy | $6 → $5 |
| 2026-09-11 | Cantor Fitzgerald | Reiterated | Overweight | $8 |
| 2026-08-06 | Wells Fargo | Target lowered | Overweight | $14 → $13 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $11 → $14 |
Total return (dividends reinvested) (MNKD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -40.4% | -37.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -40.5% | -8.9% |
| Volatility (annualized) | 74.5% | 60.5% |
| Max drawdown | -63.3% (Feb 2026→Mar 2026) | -69.0% (Nov 2024→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 3.19 |
|---|---|
| Change | ▲ 5.63% (up) |
| Previous Close | USD 3.02 |
| Open | USD 3.02 |
| Day Range | USD 3 – 3.2 |
| 52-Week Range | USD 2.23 – 6.51 |
| Volume | 3,756,529 shares |
| Market Cap | $1.03B |
| Exchange | NGM |
Technical Analysis (MNKD)
Nexqual's technical model rates MNKD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.91 (neutral) |
| vs SMA50 | Below (USD 3.75) |
| MACD | -0.16 (negative) |
Analyst Ratings (MNKD)
Wall Street analysts rate MNKD "Buy" based on 8 analysts, with a mean price target of USD 7.84 (range USD 4.75–13), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 7.84 |
| High Target | USD 13 |
| Low Target | USD 4.75 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (MNKD)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $110.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.01 vs est 0.02 ▼ miss |
| 2026-03-31 | USD -0.02 vs est 0.01 ▼ miss |
| 2025-12-31 | USD 0.01 vs est 0.03 ▼ miss |
| 2025-09-30 | USD 0.07 vs est 0.03 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (MNKD)
| Total Revenue | $393.63M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +42.90% |
| Gross Margin | +75.39% |
| Operating Margin | -0.76% |
| Profit Margin | -11.08% |
| Current Ratio | 1.72 |
| Total Cash | $111.13M |
| Total Debt | $433.83M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $13.69M (3.9% of revenue) |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (MNKD)
Nexqual rates MannKind Corporation's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -1% |
| Balance Sheet | Mixed — $111M cash vs $434M debt |
| Cash Flow | Mixed — FCF $14M (FY ended Dec 2025, 10-K), slim 3.9% margin |
| Efficiency | Mixed — No data |
Ownership (MNKD)
| Insider Ownership | +1.47% |
|---|---|
| Institutional Ownership | +57.04% |
| Shares Outstanding | 321.54M |
| Float | 297.60M |
| Short % of Float | +8.24% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (MNKD)
MannKind Corporation is led by Michael E. Castagna Pharm.D. (age 49), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Michael E. Castagna Pharm.D. (age 49) |
|---|---|
| Chief Financial Officer | Christopher B. Prentiss (age 50) |
| President of Endocrine Business Unit | Dominic Marasco R.Ph. (age 53) |
| Executive Vice President of Technical Operations | Sanjay Singh (age 59) |
Major Backers & Investors (MNKD)
Notable institutional backers of MannKind Corporation include Rubric Capital Management LP, Fidelity, Wellington Management, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 5.6% |
| Fidelity | 2.46% |
| Wellington Management | 2.44% |
| Frazier Life Sciences Management, L.P. | 2.05% |
| Deep Track Capital, Lp | 1.87% |
| 180 Wealth Advisors, LLC | 1.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 14.02% |
| Vanguard Group | 8.59% |
| State Street | 7.26% |
| Geode Capital | 2.47% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
From MannKind Corporation's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
- It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
- The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
- It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt